Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint
Acadia Pharmaceuticals' (ACAD) shares dropped 6% after its Phase 2 RADIANT study for remlifanserin in Alzheimer's disease psychosis missed the primary endpoint but met a key secondary measure. The 60 mg dose showed a -12.6 change from baseline vs. -10.4 for placebo (p=0.0603). The company will continue Phase 3 trials but drop the 30 mg dose. Safety findings were similar across groups.
How this was made
The 30-second read
Why it matters
The miss of the primary endpoint is likely to delay near‑term revenue expectations and increase volatility.
Market read
First report of trial results; immediate price impact makes it a notable trading event.
What to watch
The 60 mg dose showed nominal significance on a secondary endpoint, which could be leveraged in future communications.
Background
Acadia Pharmaceuticals is a Nasdaq‑listed biotech focused on neuropsychiatric indications.
Ticker impact
Phase 2 RADIANT study missed its primary endpoint, causing a 6% share decline.
downward pressure, potential further sell-off
First disclosure of missed primary endpoint; market reacted immediately with a 6% drop.
Market effects
Alzheimer's disease psychosis drug developers may face heightened scrutiny after this miss.
US biotech sector could see modest pullback.
Limited to biotech investors; no broad market effect.
Counterpoint
If Phase 3 data remain strong, the miss may be a temporary setback.
Key entities
- companyAcadia Pharmaceuticals Inc.
Developer of remlifanserin for Alzheimer's disease psychosis.
